Cutaneous melanoma: Taiwan experience and literature review

Chang Gung Medical Journal

Volumn 33, Issue 6, 2010, Pages 602-612

  Chang, John Wen Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acral lentiginous melanoma; Cutaneous melanoma; Taiwan

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARMUSTINE; CISPLATIN; CYTOKINE; DACARBAZINE; DACTINOMYCIN; DENDRITIC CELL VACCINE; DOCETAXEL; GANGLIOSIDE GM2; IMATINIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; MELPHALAN; NAVELBINE; PACLITAXEL; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLX 4032; PROTEIN TYROSINE KINASE INHIBITOR; QS 21; TAMOXIFEN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ADVANCED CANCER; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IN-TRANSIT METASTASIS; INJECTION SITE ULCER; LIMB PERFUSION; LIVER TOXICITY; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; MASTECTOMY; MELANOMA; METASTASIS; NEUTROPENIA; PATIENT ASSESSMENT; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION EXPOSURE; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN CANCER; SKIN ULCER; SYSTEMIC THERAPY; TAIWAN; TREATMENT DURATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

HUMANS; MELANOMA; SKIN NEOPLASMS; TAIWAN;

EID: 78651252735     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9.
2. Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J 2006;119:U2169.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
5. Shoo BA, Kashani-Sabet M. Melanoma Arising in African-, Asian-, Latino- and Native-American Populations. Semin Cutan Med Surg 2009;28:96-102.
6. Taiwan (R.O.C.) Cancer registry annual report. Taipei, Taiwan: Department of Health EY, 2006.
7. Lea CS, Scotto JA, Buffler PA, Fine J, Barnhill RL, Berwick M. Ambient UVB and melanoma risk in the United States: a case-control analysis. Ann Epidemiol 2007;17:447-53.
8. Guo HR, Yu HS, Hu H, Monson RR. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, R.O.C.). Cancer Causes Control 2001;12:909-16.
9. Green A, McCredie M, MacKie R, Giles G, Young P, Morton C, Jackman L, Thursfield V. A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control 1999;10:21-5.
10. Chang JWC, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, Kuo TT, Yang CH. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res 2004;14:537-41.
11. Soong CY, Liu HN, Ger LP, Chu TL, Syu HL, Tseng HH. Malignant melanoma: a clinicopathologic study of 22 cases. J Formos Med Assoc 1991;90:365-70.
12. Chen YJ, Wu CY, Chen JT, Shen JL, Chen CC, Wang HC. Clinicopathologic analysis of malignant melanoma in Taiwan. J Am Acad Dermatol 1999;41:945-9.
13. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am 2003;83:109-56.
14. Lavie A, Desouches C, Casanova D, Bardot J, Grob JJ, Legre R, Magalon G. Surgical management of cutaneous malignant melanoma. Ann Chir Plast Esthet 2007;52:1-13.
15. Chen H, Wu W, Wei F. Malignant Melanoma in Chinese. J Plas Surg Assoc ROC 1994;3:201-6.
16. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:39-44.
17. Garbe C, Terheyden P, Keilholz U, Kolbl O, Hauschild A. Treatment of melanoma. Dtsch Arztebl Int 2008;105:845-51.
18. Clark GS, Pappas-Politis EC, Cherpelis BS, Messina JL, Moller MG, Cruse CW, Glass LF. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control 2008;15:216-24.
19. Daniel GC. NCCN Clinical Practice Guidlines in Oncology, Melanoma V.2.2010. Available from http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed May 2010.
20. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Mozzillo N, Essner R, Glass EC. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLTI, an international multicenter trial. Ann Surg 2005;242:302-11.
21. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17.
22. Lan CCE, Hou MF, Yu HS, Chen GS, Cheng ST, Chen YW. First report of acral lentiginous melanoma treated according to result of sentinel lymph node biopsy in Taiwan. Dermatol Sinica 2001;19:282-7.
23. Liu SH, Chang WC, Kao PF, Lo YF, Yang CH, Tsai CC, Tzen KY. Lymphoscintigraphy and intraoperative gamma probe-directed sentinel lymph node mapping in patients with malignant melanoma. J Formos Med Assoc 2004;103:41-6.
24. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
25. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003;21:43-52.
26. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
27. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in highrisk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
28. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant highdose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
29. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430-6.
30. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D, EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:1189-96.
31. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241-52.
32. Pirard D, Heenen M, Melot C, Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004;208:43-8.
33. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-25.
34. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501.
35. Dummer R, Mangana J. Long-term pegylated interferonalpha and its potential in the treatment of melanoma. Biologics 2009;3:169-82.
36. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-26.
37. Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol 2009;6:70-1.
38. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, Kirkwood JM. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112:982-94.
39. Treisman J, Garlie N. Systemic therapy for cutaneous melanoma. Clin Plast Surg 2010;37:127-46.
40. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M, Stevens MF. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-3.
41. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-5.
42. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989;64:2024-9.
43. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-64.
44. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8.
45. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, Trefzer U. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006;76:59-64.
46. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7.
47. Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569-76.
48. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145-54.
49. Yang T, Ng K, Wang H, Kiu M, Wang C, Lai G. Combination chemotherapy with BCNU, Cisplatin, DTIC plus tamoxifen for metastatic malignant melanoma. J Chin Oncol Soc 1993;9:18-24.
50. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol 2009;21:15-24.
51. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001;345:1655-9.
52. Sondak VK, Liu PY, Warneke J, Vetto J, Tuthill R, Redman B, Sosman JA. Surgical resection for stage IV melanoma: a Southwest Oncology Group Trial (S9430). Proc Amer Soc Clin Oncol 2006;24:abstr 8019.
53. Sondak VK, Zager JS. Surgical management of locally advanced, in-transit, and metastatic melanoma. Amer Soc Clin Oncol 2007; education session:abstr 523.
54. Chang JWC, Peng M, Vaquerano JE, Zhou YM, Clinton RA, Hyun WC, Giedlin MA, Leong SP. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 2000;20:1329-36.
55. Chang JWC, Hsieh JJ, Shen YC, Ho E, Chuang CK, Chen YR, Liao SK, Chen JS, Leong SP, Hou MM, Chang NJ, Wang CH. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. Melanoma Res 2009;19:309-15.
56. Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, Lejeune FJ. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-12.
57. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
58. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL, Chadaram V, Herndon JE, Fraker DL, Tyler DS. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24:4196-201.
59. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47.
60. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88:1-3.
61. Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30:1107-12.
62. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36.
63. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27:abstr 9000.
64. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
65. Carvajal R, Chapman P, Wolchok J, Cane L, Teitcher J, Lutzky J, Pavlick AC, Bastian BC, Antonescu CR, Schwartz GK. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009;27:abstr 9001.
66. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.